An observational study in Inflammatory Bowel Diseases, sponsored by University of Pittsburgh. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-03.
Sponsored by University of Pittsburgh · Observational
The vast majority of what is known about the extrinsic innervation of the visceral was obtained through the study of preclinical models, primarily rats and mice. Given a growing list of important species differences, the investigators wish to determine the extent to which what scientists think they know about the control of visceral afferent excitability learned through the study of rodents holds true for humans. The investigators wish to establish an ex-vivo preparation using intestine surgically removed for the treatment of cancer, ischemia, etc, that would normally be disposed of as medical waste, to study the properties of the extrinsic innervation of the intestine. Tissue will be recovered in the OR, taken back to the lab, and evoked activity in the neurons innervating the intestine will be studied with extracellular recording techniques. Pharmacological approaches will be used to characterize the ion channels/receptors controlling the excitability of visceral afferents. After recording, tissue may be further analyzed with biochemical approaches such as western blot, PCR, and/or flow cytometry.
Visceral pain disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD; Crohn's disease, ulcerative colitis) remain a significant health problem both because of the large number of people who suffer from these disorders and because there are few, if any consistently effective therapeutic interventions. Thus, the goal of this project is to identify novel therapeutic approaches for the treatment of visceral pain.
The sensation of visceral pain is transmitted from visceral structures to the central nervous system via sensory neurons where the increase in pain associated with IBS and IBD is due, at least in part to increases in the excitability of these sensory neurons. Virtually all that scientists know about visceral sensory neurons was learned through the study of non-human species, in particular, rats and mice. A growing body of evidence suggests that many of the discoveries made in these species have failed to translate into more effective treatments because of species differences. To address this gap in knowledge, the investigators have proposed to study human tissue. Based on the investigator's preclinical data, they will start with a focus on GABA receptors, but will also explore other ionotropic receptors (for serotonin and ATP), as well as voltage gated ion channels. The investigators hypothesize that the dearth of effective treatments for visceral pain is due, at least in part, to species differences in the channels controlling the excitability of visceral sensory neurons. Electrophysiological techniques combined with pharmacological approaches will be used for a functional analysis of visceral afferents, and these endpoints will be complimented by biochemical, anatomical, and molecular biological analyses. Electrophysiological analysis of tissue will be performed on the day of surgery. Tissue will be processed and stored for biochemical, anatomical, and molecular biological analyses on the day of surgery, but analyzed once per month if it is possible to recover tissue from two patients per week.
1,460 studies on the registry are indexed under Inflammatory Bowel Diseases; 437 are open to participants now.
Browse Inflammatory Bowel Diseases studies →University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
All subjects (>18), younger than 85, scheduled for abdominal surgery involving the removal of GI tissue for therapeutic purposes.
Exclusion Criteria:
Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
Single unit activity in afferents innervating intestine specimen
The success of this ex vivo study will depend on the ability to record from afferent providing extrinsic innervation to the intestine.
Time frame: The presence of activity will be assessed immediately in each specimen recovered, day 1 of surgery.
The ability to identify receptive fields of visceral afferents in the intestine
An electrical search strategy will be used to identify receptive fields in the ex vivo preparation
Time frame: The presence of receptive fields will be assessed immediately in each specimen recovered, day 1 of surgery.
Pharmacological characterization of isolated visceral afferent
The impact of GABAA agonists and/or agonist/antagonist combinations will be assessed in the ex vivo preparation
Time frame: Pharmacological analysis will be performed immediately on each specimen recovered day 1 of surgery.
Changes in threshold of action potential generation in response to inflammatory mediators and/or GABAA agonists or agonist/antagonist combinations.
The pharmacological characterization of isolated units will involve the assessment of changes in activity evoked with stretch of the intestine.
Time frame: Excitability will be analyzed immediately on each specimen recovered, day 1 of surgery.
Biochemical characterization of GABAA receptor signaling molecules in human intestine
Biochemical approaches such as western blot will be used to assess the presence and density of GABAA receptor signaling machinery (receptors, GABA transporters, etc), in human intestine. This analysis will be performed in tissue not used for pharmacological analysis.
Time frame: Tissue for biochemical analysis will be flash frozen on day 1 of surgery.
Anatomical characterization of GABAA receptor signaling molecules in human intestine
Anatomical approaches such as immunohistochemistry will be used to assess the presence and density of GABAA receptor signaling machinery (receptors, GABA transporters, etc), in human intestine. This analysis will be performed in tissue not used for pharmacological analysis.
Time frame: Tissue for anatomical analysis will be immersion fixed on day 1 of surgery.
Molecular biological characterization of GABAA receptor signaling molecules in human intestine
Molecular biological approaches such as semi-quantitative PCR will be used to assess the presence and density of GABAA receptor signaling machinery (receptors, GABA transporters, etc), in human intestine. This analysis will be performed in tissue not used for pharmacological analysis.
Time frame: Tissue for molecular biological analysis will be flash frozen on day 1 of surgery.
Plan to share: No — All data generated from this study will be made publicly available through publications.
No publications or documents are linked to this record.
This study is withdrawn, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Pittsburgh